Literature DB >> 16394908

An open-label study to evaluate the safety and efficacy of tissue plasminogen activator in treatment of severe frostbite.

John A Twomey1, George L Peltier, Richard T Zera.   

Abstract

BACKGROUND: Severe frostbite can have devastating consequences with loss of limbs and digits. One of the mechanisms of cold injury to human tissue is vascular thrombosis. The effect of tissue plasminogen activator (tPA) and heparin in limb and digit preservation in severe frostbite patients has not been previously studied.
METHODS: Intra-arterial (6 patients) or intravenous (i.v., 13 patients) tPA and IV heparin were used in patients with severe frostbite. All patients between January 1, 1989 and February 1, 2003 with severe frostbite not improved by rapid rewarming, with absent Doppler pulses in distal limb or digits, without perfusion by Technetium (Tc) 99m three-phase bone scan, and no contraindication to tPA use were eligible. Efficacy was assessed on the basis of predicted digit amputation before therapy, given the clinical and Tc-99m scan results, versus partial or complete digits removed.
RESULTS: There were no complications with i.v. tPA. Two patients with intra-arterial TPA had bleeding complications. We know from historical Tc-99m scan data which digits were at risk for amputation. In this study, there were 174 digits at risk in 18 patients and only 33 were amputated.
CONCLUSION: Intravenous tPA and heparin after rapid rewarming is safe and reduced predicted digit amputations considerably. Patients with no response to thrombolytic therapy were those with more than 24 hours of cold exposure, warm ischemia times greater than 6 hours, or evidence of multiple freeze-thaw cycles. Our algorithm for treatment of severe frostbite now includes use of i.v. tPA for patients without contraindications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16394908     DOI: 10.1097/01.ta.0000195517.50778.2e

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  17 in total

Review 1.  [Three case reports of frostbite. Management and literature].

Authors:  O Goertz; N Kapalschinski; T Hirsch; H H Homann; A Daigeler; L Steinstraesser; H-U Steinau; S Langer
Journal:  Unfallchirurg       Date:  2011-07       Impact factor: 1.000

2.  Frostbite.

Authors:  Adrian E Flatt
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-07

Review 3.  Frostbite: Spectrum of Imaging Findings and Guidelines for Management.

Authors:  John D Millet; Richard K J Brown; Benjamin Levi; Casey T Kraft; Jon A Jacobson; Milton D Gross; Ka Kit Wong
Journal:  Radiographics       Date:  2016-08-05       Impact factor: 5.333

4.  Treatment of severe frostbite with iloprost in northern Canada.

Authors:  Alexander Poole; Josianne Gauthier
Journal:  CMAJ       Date:  2016-04-04       Impact factor: 8.262

5.  Thrombolytic therapy in the acute management of frostbite injuries.

Authors:  Christopher Wagner; Christopher J Pannucci
Journal:  Air Med J       Date:  2011 Jan-Feb

Review 6.  The utility of bone scintigraphy with SPECT/CT in the evaluation and management of frostbite injuries.

Authors:  Matthew S Manganaro; John D Millet; Richard Kj Brown; Benjamin L Viglianti; Daniel J Wale; Ka Kit Wong
Journal:  Br J Radiol       Date:  2018-11-01       Impact factor: 3.039

7.  The Triaging and Treatment of Cold-Induced Injuries.

Authors:  Christoph Sachs; Marcus Lehnhardt; Adrien Daigeler; Ole Goertz
Journal:  Dtsch Arztebl Int       Date:  2015-10-30       Impact factor: 5.594

8.  The Use of tPA in the Treatment of Frostbite: A Systematic Review.

Authors:  Richard L Hutchison; Hannah M Miller; Spencer K Michalke
Journal:  Hand (N Y)       Date:  2018-09-19

9.  Protocoled thrombolytic therapy for frostbite improves phalangeal salvage rates.

Authors:  Rosemary Elizabeth Paine; Elizabeth Noel Turner; Daniel Kloda; Carolyne Falank; Bruce Chung; Damien Wilson Carter
Journal:  Burns Trauma       Date:  2020-04-10

10.  Interventions for frostbite injuries.

Authors:  Anne Kathrine Lorentzen; Christopher Davis; Luit Penninga
Journal:  Cochrane Database Syst Rev       Date:  2020-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.